MedTrace Logo

Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease

NCT01569516 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 288

Last updated 2012-04-09

No results posted yet for this study

Summary

The main purpose of this study is to evaluate the safety and efficacy of Octohydroaminoacridine Succinate tablets and find the optimal dose in patients with mild to moderate Alzheimer's Disease.

Conditions

Interventions

DRUG

Octohydroaminoacridine Succinate Tablets

1mg, tid

DRUG

Octohydroaminoacridine Succinate Tablets

1st-2nd week, 1mg, tid 3rd -16th week, 2mg, tid

DRUG

Octohydroaminoacridine succinate Tablets

1st-2nd week, 1mg, tid, 3rd -4th week, 2mg, tid, 5th-16th week, 4mg, tid

DRUG

Placebo

0mg, tid

Sponsors & Collaborators

  • Beijing Bionovo Medicine Development Co., Ltd.

    collaborator OTHER

  • Changchun Huayang High-tech Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Shifu Xiao, MD · Shanghai Mental Health Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2012-07-31
Completion
2012-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01569516 on ClinicalTrials.gov